Search research articles
Contact Us
Filters
Showing results (11-20 of 178) with videos related to
Page
of 18
Sort By:
Oncoimmunology
|
April 9, 2016
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Ali Roghanian, Mark S Cragg, Björn Frendéus
Nature Immunology
|
July 12, 2023
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Nature Immunology
|
July 6, 2023
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Nature Immunology
|
August 23, 2023
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Frontiers in Immunology
|
May 14, 2023
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
Osman Dadas, Ayse Ertay, Mark S Cragg
Seminars in Immunology
|
December 19, 2024
The complement system in clinical oncology: Applications, limitations and challenges
Daniel Ajona, Mark S Cragg, Ruben Pio
Frontiers in Immunology
|
July 14, 2020
Editorial: Roles of Fc Receptors in Disease and Therapy
Latha P Ganesan, Mark S Cragg, Gestur Vidarsson
The International Journal of Biochemistry & Cell Biology
|
December 15, 2010
B cells--masters of the immunoverse
Andrew T Vaughan, Ali Roghanian, Mark S Cragg
Cancers
|
October 13, 2021
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies
Khiyam Hussain, Mark S Cragg, Stephen A Beers
Pharmacological Research
|
July 19, 2015
Antibody modulation: Limiting the efficacy of therapeutic antibodies
Andrew T Vaughan, Mark S Cragg, Stephen A Beers
Page
of 18
Search research articles
Search
Showing results (11-20 of 178) with videos related to
Sort By:
Page
of 18
Oncoimmunology
|
April 9, 2016
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Ali Roghanian, Mark S Cragg, Björn Frendéus
Nature Immunology
|
July 12, 2023
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Nature Immunology
|
July 6, 2023
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Nature Immunology
|
August 23, 2023
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg
Frontiers in Immunology
|
May 14, 2023
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
Osman Dadas, Ayse Ertay, Mark S Cragg
Seminars in Immunology
|
December 19, 2024
The complement system in clinical oncology: Applications, limitations and challenges
Daniel Ajona, Mark S Cragg, Ruben Pio
Frontiers in Immunology
|
July 14, 2020
Editorial: Roles of Fc Receptors in Disease and Therapy
Latha P Ganesan, Mark S Cragg, Gestur Vidarsson
The International Journal of Biochemistry & Cell Biology
|
December 15, 2010
B cells--masters of the immunoverse
Andrew T Vaughan, Ali Roghanian, Mark S Cragg
Cancers
|
October 13, 2021
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies
Khiyam Hussain, Mark S Cragg, Stephen A Beers
Pharmacological Research
|
July 19, 2015
Antibody modulation: Limiting the efficacy of therapeutic antibodies
Andrew T Vaughan, Mark S Cragg, Stephen A Beers
Page
of 18